DXNVX Signs Agreement with Stanford University in the US for Universal COVID-19 Vaccine Introduction

DXVX announced on the 19th that it has recently completed a contract with Stanford University in the United States to introduce a universal COVID-19 vaccine.

Through this contract, DXVX has secured worldwide research, development, and commercialization rights for the vaccine. The vaccine substance has successfully completed Phase 1 clinical trials in the United States and South Africa. Based on Phase 1, DXVX plans to proceed with global Phase 2 trials.

The new drug candidate being introduced is a vaccine aimed at preventing the virus that causes COVID-19. Unlike existing mRNA vaccines, it uses a nanoparticle-based approach. This technology is designed to be universally applicable to the dominant variants identified so far and has the advantage of being developed as a conveniently administered vaccine via oral or nasal routes.

Notably, the inventor, Professor Peter Kim of Stanford University's Department of Biochemistry, is a world-renowned scientist who first elucidated the HIV cell fusion mechanism and was nominated for the Nobel Prize. He also served as the head of research at the multinational pharmaceutical company Merck. The contract and collaboration were established through the persistent efforts and persuasion of Lim Jong-yoon, chairman of the Kori Group and the largest shareholder of DXVX, earning Professor Kim's trust.

With this introduction contract, DXVX is expected to accelerate clinical trials and commercialization. The universal vaccine capable of responding to all COVID-19 variants is anticipated to yield positive results. This reflects DXVX's strong determination to secure vaccine sovereignty by preparing in advance for a potential second pandemic.

DXVX CEO Kwon Kyu-chan stated, “We are very pleased to have signed this contract with Stanford University. We would like to thank the Stanford University officials once again and will work together to enable rapid commercialization and prepare for the second pandemic.” He added, “Starting with this contract, we plan to establish various partnership models with Stanford University.”